Argenx (ARGX)
(Delayed Data from NSDQ)
$372.80 USD
+4.20 (1.14%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $372.88 +0.08 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ARGX 372.80 +4.20(1.14%)
Will ARGX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ARGX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARGX
Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?
What's in Store for Puma Biotechnology (PBYI) in Q1 Earnings?
ARGX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Intellia (NTLA) to Report Q1 Earnings: What's in the Cards?
GSK Gears Up for Q1 Earnings: Here's What to Expect
Viking (VKTX) to Report Q1 Earnings: What's in the Cards?
Other News for ARGX
Piper Sandler Sticks to Its Buy Rating for Argenx Se (ARGX)
Artisan International Fund Q1 2024 Commentary
Baron Health Care Fund Q1 2024 Shareholder Letter
Analysts’ Top Healthcare Picks: Elevance Health (ELV), Argenx Se (ARGX)
Maintaining the Edge: Argenx’s Hold Rating Amidst Rising Competition and Promising Therapy Results